Role Of Cholesterol-lowering Medications (Statins) In the Progression of Age-Related Macular Degeneration

Centre for Eye Research Australia0 个研究点目标入组 300 人开始时间: 2005年9月6日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•(1) The ability to assess the macula in at least one eye, (2) VA better than or equal to 6/18 in the study eye(s). (3) High risk drusen in both eyes: one or more large soft druse (125 microns), or >10 intermediate drusen (62.5 microns) ORLate AMD (CNV, GA) in one eye and any drusen or pigment change in the study eye.Note: the study eye is allowed to have non-central GA and/or non-neovascular PED (4) cholesterol level within the normal limits according to the person's medical history (5) not currently on any cholesterol-lowering medication.

•(1) Medical and ophthalmic conditions which potentially affects visual function, including visually significant cataract (as defined by WILMER's grading method-that is nuclear opacity score of 2.00 or greater, cortical opacity score of greater than 3, any posterior subcapsular cataract), history of diabetes and glaucoma(2) Use of medications which may affect visual function, such as plaquenil, chloroquine, major tranquilizers.(3) cholesterol levels outside the normal limits given person's medical history.(a)Existing coronary heart disease:-- cholesterol > 4 mmol/L(b) Diabetics, people with hypertension, peripheral vascular disease, family history of hypercholesterolaemia or coronary heart disease:-- cholesterol > 6.5mmol/L or cholesterol > 5.5 if HDL <1.0mmol/L(c) people with HDL <1.0mmol/L:--cholesterol >6.5mmol/L(d) men aged 35 to 75 years or postmenopausal women up to 75 years:-- cholesterol >7.5 or triglycerides > 4.0mmol/L(e) people with none of the above:--cholesterol >9.0 or triglycerides >8.0mmol/L(4)Statins is clinically contraindicated:(a) Allergy(b) ALT > 2 times the upper limit of normal(c) Previous severe adverse reactions to statin.

发起方